Reuters Health News Summary

Moderna to seek U.S. and EU authorization for its vaccine on Monday Moderna Inc will apply for U.S. and European emergency authorization for its COVID-19 vaccine on Monday after full results from a late-stage study showed it was 94.1% effective with no serious safety concerns, the company said.

Following is a summary of current health news briefs. South Korea considers more vaccine buys as coronavirus cases spike

South Korea's ruling party has called for the country to buy millions of additional coronavirus vaccine doses after a spike in infection numbers raised concerns about the government's existing plans. South Korea already plans to secure enough doses to vaccinate 30 million people, or about 60% of the population, but Democratic Party lawmakers said they would appropriate funds to buy doses for at least 44 million people. What you need to know about the coronavirus right now

Here's what you need to know about the coronavirus right now: Singapore studies pregnancy puzzle Cambodia PM bans mass gatherings to fight rare coronavirus outbreak

Cambodian Prime Minister Hun Sen banned wedding parties and gatherings of more than 20 people on Monday, as authorities moved quickly to try to thwart a coronavirus outbreak after announcing rare cases of community transmission. Fifteen people have so far tested positive from 3,332 tested since Sunday, the health ministry said, all linked to a 56-year-old woman who had travelled to the country's two biggest cities since Nov. 20. Moderna to seek U.S. and EU authorization for its vaccine on Monday

Moderna Inc will apply for U.S. and European emergency authorization for its COVID-19 vaccine on Monday after full results from a late-stage study showed it was 94.1% effective with no serious safety concerns, the company said. Moderna also reported that the vaccine's efficacy rate was consistent across age, race, ethnicity and gender demographics as well as having a 100% success rate in preventing severe cases of a disease that has killed nearly 1.5 million people. England's COVID-19 infections down 30% during national lockdown: survey

COVID-19 infections have fallen by 30% during England's month-long national lockdown and the virus is now in retreat, a large-scale study of more than 100,000 volunteers showed on Monday. England began its second national lockdown on Nov. 5 to curb rapidly rising infections and protect its health system. The country is due to return to a regional approach to restrictions from Dec. 2. Q&A: Where are we in the COVID-19 vaccine race?

Large global trials of several COVID-19 vaccine candidates involving tens of thousands of participants are well underway with some having gathered sufficient data to seek emergency use authorisation. The following is what we know about the race to deliver vaccines to help end the coronavirus pandemic that has claimed more than 1.45 million lives worldwide: French health body says nursing homes should get COVID-19 vaccine first

France's top health advisory body said on Monday it had recommended COVID-19 vaccinations should target retirement homes residents and their staff first when doses reach the country. Haute Autorite de la Sante (HAS) suggested rolling out the campaign in stages and on a voluntary basis, like in many other countries. New York City public schools will begin to reopen with weekly COVID-19 testing

New York City's public schools will begin to reopen for in-person learning on Dec. 7, starting with elementary schools for students whose parents agree to a weekly testing regimen for the novel coronavirus, Mayor Bill de Blasio announced on Sunday. The schools, which make up the country's largest school system, were closed less than two weeks ago after the citywide rate of coronavirus tests coming back positive exceeded a 3% benchmark agreed to by the mayor and the teachers' union.

Singapore studies COVID-19 pregnancy puzzle after baby born with antibodies Doctors are studying the impact of COVID-19 on pregnant women and their unborn babies in Singapore, where an infant delivered by an infected mother earlier this month had antibodies against the virus but did not carry the disease. The ongoing study among the city-state's public hospitals adds to international efforts to better understand whether the infection or antibodies can be transferred during pregnancy, and if the latter offers an effective shield against the virus.

Novavax sees start of U.S. COVID-19 vaccine trial in coming weeks after second delay Vaccine maker Novavax Inc said on Monday it has pushed back the start of a U.S.-based, late-stage trial for its experimental COVID-19 vaccine and now expects it to begin in the coming weeks instead of November. It is the second time that Novavax, which already has a late-stage UK trial underway, has rescheduled the Phase 3 trial after first flagging an October start, hampered by issues in scaling up its manufacturing.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)